Documents relating to the use of the INTERCEPT™ Blood System. Search for brochures, instructions for use, manuals, technical data sheets, and more.

McCullough J, et al. examines the costs associated with the replacement of specific tests, as well as procedures and practices for the production of apheresis platelets that can be eliminated with the adoption of pathogen reduction. Five participating US institutions were surveyed to assess the potential replacement of current tests (such as bacterial detection) and potential future tests such as those for dengue and Babesia. And the possible savings as a result of decreased platelet wastege should seven-day storage licensing become available with pathogen reduction.
Richard Benjamin talks about the robustness of the INTERCEPT™ Blood system in inactivating different bacterial strains 12 to 30 hours after inoculation of apheresis or whole blood derived platelets.
Learn more about how double dose buffy coat platelet production supported the affordability of the INTERCEPT™ Blood System for platelets at the Karolinska University Hospital in Stockholm, Sweden
Case study - Karolinska University Hospital, Stockholm, Sweden
Pathogen Inactivation and INTERCEPT will be included in 14 poster presentations at the ISBT 2017 in Copenhagen.
Richard Benjamin talks about the prevalence of bacterial sepsis and fatalities in different countries throughout the world. The impact of active versus passive haemovigilance in picking up the symptoms of bacterial sepsis after platelet transfusion, the prevalence of bacterial sepsis after the implementation of different bacterial detection systems and explains the 2016 draft guidance from FDA to enhance the bacterial safety and availability of platelets in the USA.